Insider · CIK 0001522478
Kevin D Freeman
Files at GALT (GALECTIN THERAPEUTICS INC). First filing Oct 16, 2024, latest Dec 23, 2025.
Kevin D Freeman files SEC Form 4 as director at GALT (GALECTIN THERAPEUTICS INC). Since Oct 16, 2024, Kevin D Freeman has reported 7 open-market buys worth $112k and 0 open-market sells worth $0, the latest filed on Dec 23, 2025.
A track record needs three past buys with six months of prices behind them; Kevin D Freeman has 2, so none is measured yet.
The newest scored trade: bought $20k of GALT on Dec 23, 2025, filed Dec 23, 2025, scored 19 (weak), under a 10b5-1 plan. In the last 12 months: 3 buys worth $59k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GALT: GALECTIN THERAPEUTICS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 19Weak | GALECTIN THERAPEUTICS INC | $20k 5,500 shares | +11% | +375% from low-39% from high | |
| 19Weak | GALECTIN THERAPEUTICS INC | $20k 5,500 shares | +11% | +375% from low-39% from high | |
| 34Weak | GALECTIN THERAPEUTICS INC | $20k 5,500 shares | +11% | +375% from low-39% from high | |
| 26Weak | GALECTIN THERAPEUTICS INC | $14k 5,000 shares | +11% | +244% from low-12% from high | |
| 41Moderate | GALECTIN THERAPEUTICS INC | $8,134 10,000 shares | +29% | - | |
| 28Weak | GALECTIN THERAPEUTICS INC | $3,432 1,300 shares | +4% | - | |
| 34Weak | GALECTIN THERAPEUTICS INC | $27k 10,000 shares | +35% | - |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 16, 2026 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 21, 2026 |
| Dec 23, 2025 | GALT GALECTIN THERAPEUTICS INC | POpen-market purchase Common Stock10b5-1 | +5,500 | $3.55 | $20k | 55,269 | Dec 23, 2025 |
| Dec 23, 2025 | GALT GALECTIN THERAPEUTICS INC | POpen-market purchase Common Stock10b5-1 | +5,500 | $3.55 | $20k | 55,269 | Dec 23, 2025 |
| Dec 23, 2025 | GALT GALECTIN THERAPEUTICS INC | POpen-market purchase Common Stock | +5,500 | $3.55 | $20k | 55,269 | Dec 23, 2025 |
| Jul 17, 2025 | GALT GALECTIN THERAPEUTICS INC | POpen-market purchase Common Stock | +5,000 | $2.90 | $14k | 49,769 | Jul 18, 2025 |
| Jan 23, 2025 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 27, 2025 |
| Dec 24, 2024 | GALT GALECTIN THERAPEUTICS INC | POpen-market purchase Common Stock | +10,000 | $0.81 | $8,134 | 44,769 | Dec 26, 2024 |
| Oct 17, 2024 | GALT GALECTIN THERAPEUTICS INC | POpen-market purchase Common Stock | +1,300 | $2.64 | $3,432 | 34,769 | Oct 17, 2024 |
| Oct 16, 2024 | GALT GALECTIN THERAPEUTICS INC | POpen-market purchase Common Stock | +5,000 | $2.70 | $14k | 33,469 | Oct 16, 2024 |
| Oct 16, 2024 | GALT GALECTIN THERAPEUTICS INC | POpen-market purchase Common Stockindirect: By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC | +5,000 | $2.70 | $14k | 80,000 | Oct 16, 2024 |
Questions about Kevin D Freeman
Answered from the filings on this page, as of the latest one.
Is Kevin D Freeman buying or selling?
In the last 12 months Kevin D Freeman reported 3 open-market buys worth $59k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $20k of GALT on Dec 23, 2025. Grants, option exercises and tax withholding are not counted.
How did Kevin D Freeman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kevin D Freeman has 2.
Where does Kevin D Freeman file Form 4?
Kevin D Freeman has filed Form 4 at GALT (GALECTIN THERAPEUTICS INC). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.